FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL							
OMB Number:	3235-0287						
Estimated average burden							
hours per response:	0.5						

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person * CATLIN AVERY W					2. Issuer Name and Ticker or Trading Symbol Corbus Pharmaceuticals Holdings, Inc. [CRBP]										ionship of Reporting Pe all applicable) Director		erson(s) to Issuer 10% Own		ner
(Last)	(First)	(N	liddle)	3. Date of Earliest Transaction (Month/Day/Year) 05/18/2023										Officer (g below)	ve title		Other (s below)	pecify	
C/O CORBUS PHARMACEUTICALS HOLDINGS, INC 500 RIVER RIDGE DRIVE				4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Indiv	Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person						
(Street) NORWOOD	MA	02	2062												Form filed	d by More t	han O	ne Reportino	g Person
(City)	(State)	(Z	ip)																
		Ta	able I - Nor	n-Deriv	vative	e Se	curitie	s Acq	juired, D	isp	osed of	, or B	Benefic	ially Ow	ned			,	
Date				Date	nth/Day/Year)		2A. Deemed Execution Date, if any (Month/Day/Year)		Transaction Dispose Code (Instr.			rities Acquired (A) or ed Of (D) (Instr. 3, 4 and 5			5. Amount Securities Beneficially Following I	ly Owned or In Reported on(s)		Direct (D) irect (I) 4)	7. Nature of Indirect Beneficial Ownership
									Code	v	Amount (A) or (D)		Price	Transaction (Instr. 3 and				(Instr. 4)	
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year	Co	Transaction Code (Instr.		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)			8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option				Co	ode	v	(A)	(D)	Date Exercisabl		xpiration ate	Title		Amount or Number of Shares		(Instr. 4)	on(S)		
(right to buy)	\$9.96	05/18/2023			A		5,300		(1)	05	5/18/2033		nmon lock	5,300	\$0.00	5,300		D	

Explanation of Responses:

1. The annual option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan. The option will vest 100% on the one year anniversay from the date of grant.

Remarks:

/s/ Sean Moran, attorney-in-fact for Avery Catlin 05/22/2023

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.